Board of Directors

Scott Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Envista and NuVasive.

David Roman was appointed President & Chief Executive Officer in July 2022 and also continues to serve as CFO. He joined Acutus in March 2021 as Chief Financial Officer bringing over 15 years of experience in the medical technology industry. Previously, Roman served as Vice President, Strategy and FP&A for Baxter International, Inc., where he held roles of increasing responsibility since 2016. Prior to joining Baxter, he was a managing director at Goldman, Sachs & Co., leading the firm’s U.S. medical technology equity research team. Roman began his professional career in 2004 at Morgan Stanley, where he also covered the medical technology sector as a research analyst. Roman earned his BA Degree from the University of Pennsylvania.

Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor at Longitude Capital and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an MD from Mayo Clinic, an MPH in Quantitative Methods from Harvard University, and an MBA from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.

Dr. David Bonita is a Private Equity Partner at OrbiMed, where he serves on the boards of Loxo Oncology, Kyn Therapeutics, Clementia Pharmaceuticals, Tricida, Prelude Therapeutics, ViewRay, SI Bone and Keystone Heart. He previously served on the boards of Enobia Pharma, CardiAQ and Ambit Bioscience. Prior to joining OrbiMed, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS. He has published several scientific articles in peer-reviewed journals based on research performed at the Harvard Medical School. Dr. Bonita received his AB degree magna cum laude in Biological Sciences from Harvard University and his joint MD/MBA from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.

Dr. Marzouk is currently the U.S. President of GenesisCare, a position she has held since August 2022. Previously, she has been the President of CareMore Health and Aspire Health, subsidiaries of Elevance; Managing Director, Health and Global Health Innovation, of AXA health insurance and health services business in Asia; and Cardinal Health’s Medical Segment Chief Medical Officer. Dr. Marzouk also served in the U.S. Army on active duty , where she practiced as a neurosurgeon and served in Iraq as a Major. She received an MBA from The Fuqua School of Business, Duke University, an MD from St. Louis University School of Medicine, and a BA from the Washington University in St. Louis. Dr. Marzouk also advises health technology companies and serves on the advisory boards in the healthcare industry.

Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. Ms. Pellegrini has previously served as Vice President of Global Commercial Operations for Abbott Vascular, where she was responsible for driving approximately $3 billion in revenue, and as CEO and President at Autonomic Technologies, Inc., leading a turnaround of its European commercial business and driving U.S. market access. Ms. Pellegrini has also held positions in leadership, global business development, strategy and commercial with Thoratec Corporation and Johnson & Johnson. She earned both a B.S. and an M.B.A. from Santa Clara University.

Since March 2019, John Sheridan has been the President and Chief Executive Officer of Tandem Diabetes Care, Inc., a medical device company specializing in the design, development and commercialization of products for people with insulin-dependent diabetes. He has been a member of Tandem’s Board of Directors since June 2019 and a member of the executive management team since 2013. Prior to joining Tandem Diabetes Care, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.

Jason Garland has served as a member of our board of directors and chair of our Audit Committee since August 2022. Jason brings more than 20 years of extensive global financial experience and currently serves as Executive Vice President & Chief Financial Officer of Integer Holdings Corp (NYSE: ITGR) since 2018. Previously, Garland was Divisional Vice President and Chief Financial Officer for both the Global Sales and Diamond & Jewelry Supply divisions of Tiffany & Co. Prior to that, Garland held progressively challenging leadership roles across multiple complex and diverse GE businesses, including serving as Chief Financial Officer for GE’s Industrial Solutions business, Chief Risk Manager for GE Aviation Services, senior financial leadership roles at GE’s Oil and Gas business, and as a member of GE’s Corporate Audit staff. He completed GE’s two-year manufacturing leadership program and is a certified Six Sigma Black Belt. Garland received a B.S., Chemical Engineering, from the University of New Hampshire, Durham.